Starting from Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA
While semaglutide targets GLP-1 receptors, tirzepatide, marketed as Mounjaro, offers a dual mechanism by also acting on GIP receptors, enhancing metabolic outcomes
Limited access to GLP-1s in low-income and high-obesity regions threatens to widen existing health inequities, particularly in rates of diabetes, cardiovascular disease, and mobility-related conditions
Weight regain during breaks follows a predictable pattern
Regardless of the healthcare professional involved, patients should always be informed about their treatment options and actively engaged in decisions that reflect their individual health goals